[4]
Radice, P.; Cama, A.; Mariani-Costantini, R. Molecular genetics of polyposis and hereditary colorectal cancer. Forum, 1996, 6, 275-291.
[9]
Nazemalhosseini Mojarad, E.; Kuppen, P.J.; Aghdaei, H.A.; Zali, M.R. The CpG island methylator phenotype (CIMP) in colorectal cancer. Gastroenterol. Hepatol. Bed Bench, 2013, 6, 120-128.
[10]
Worthley, D.L.; Leggett, B.A.; Aghdaei, H.A.; Zali, M.R. Colorectal cancer: Molecular features and clinical opportunities. Clin. Biochem. Rev., 2010, 31, 31-38.
[34]
(a) Wu, Z.; Guo, H-F.; Xu, H.; Cheung, N-K.V. Development of a tetravalent anti-gpa33/anti-cd3 bispecific antibody for colorectal cancers. Mol. Cancer Ther, 2018, 17, 2164-2175.;
(b) Rageul, Z.; Mottier, S.; Jarry, A.; Shah, Y.; Théoleyre, S.; Masson, D.; Laboisse, C.L.; Denis, M.G. KLF4-dependent, PPARgamma-induced expression of GPA33 in colon cancer cell lines. Int. J. Cancer, 2009, 125, 2802-2809.
[45]
(a) Mita, A.C.; Mita, M.M.; Nawrocki, S.T.; Giles, F.J. Survivin: Key regulator of mitosis and apoptosis and novel target for cancer therapeutics. Clin. Cancer Res., 2008, 14, 5000-5005.;
(b) Cai, Y.; Ma, W.; Cao, L.; Li, H.; Jiang, Y.; Lu, N.; Yin, Y. Effect of survivin on tumor growth of colorectal cancer in vivo. Int. J. Clin. Exp. Pathol., 2015, 8, 13267-13672.
[50]
Polin, R.A.; Abman, S.H.; Rowitch, D.; Benitz, W.E. Fetal and Neonatal Physiology, 5th ed; Elsevier: Philadelphia, PA, USA, 2017.
[62]
Deschner, EE; Godbold, J; Lynch, HT Rectal epithelial cell proliferation in a group in young adults. Cancer, 1988, 61, 2286-2290.39.
[63]
Grady, W.M.; Markowitz, S. Colorectal cancer: Genetic alterations. In: Gastrointestinal oncology: principles and practice; Kelsen, D.; Daly, J.; Kern, S.; Levin, B.; Tepper, J., Eds.; Lippincott Williams & Wilkins: Philadelphia, 2002; pp. 685-702.
[64]
Fearon, E.R.; Bommer, G.T. Molecular biology of colorectal cancer. DeVita, Hellman, and Rosenberg’s cancer: principles & practice of oncology; DeVita, V.T., Jr; Lawrence, T.S.; Rosenberg, S.A., Eds.; Lippincott Williams & Wilkins: Philadelphia, 2008, Vol. 1, pp. 1218-1231.
[82]
Grady, W.M.; Markowitz, S.D. TGF-β signaling pathway and tumor suppression. In: The TGF-β family; Derynck, R.; Miyazano, K., Eds.; Cold Spring Harbor Laboratory Press: Cold Spring Harbor, NY, 2008; pp. 889-938.
[86]
Wood, L.D.; Parsons, D.W.; Jones, S.; Lin, J.; Sjöblom, T.; Leary, R.J.; Shen, D.; Boca, S.M.; Barber, T.; Ptak, J.; Silliman, N.; Szabo, S.; Dezso, Z.; Ustyanksky, V.; Nikolskaya, T.; Nikolsky, Y.; Karchin, R.; Wilson, P.A.; Kaminker, J.S.; Zhang, Z.; Croshaw, R.; Willis, J.; Dawson, D.; Shipitsin, M.; Willson, J.K.V.; Sukumar, S.; Polyak, K.; Park, B.H.; Pethiyagoda, C.L.; Pant, P.V.K.; Ballinger, D.G.; Sparks, A.B.; Hartigan, J.; Smith, D.R.; Suh, E.; Papadopoulos, N.; Buckhaults, P.; Markowitz, S.D.; Parmigiani, G.; Kinzler, K.W.; Velculescu, V.E.; Vogelstein, B. The genomic landscapes of human breast and colorectal cancers.
Science, 2007,
318(5853), 1108-1113.
[
http://dx.doi.org/10.1126/science.1145720] [PMID:
17932254]
[93]
Davies, H.; Bignell, G.R.; Cox, C.; Stephens, P.; Edkins, S.; Clegg, S.; Teague, J.; Woffendin, H.; Garnett, M.J.; Bottomley, W.; Davis, N.; Dicks, E.; Ewing, R.; Floyd, Y.; Gray, K.; Hall, S.; Hawes, R.; Hughes, J.; Kosmidou, V.; Menzies, A.; Mould, C.; Parker, A.; Stevens, C.; Watt, S.; Hooper, S.; Wilson, R.; Jayatilake, H.; Gusterson, B.A.; Cooper, C.; Shipley, J.; Hargrave, D.; Pritchard-Jones, K.; Maitland, N.; Chenevix-Trench, G.; Riggins, G.J.; Bigner, D.D.; Palmieri, G.; Cossu, A.; Flanagan, A.; Nicholson, A.; Ho, J.W.C.; Leung, S.Y.; Yuen, S.T.; Weber, B.L.; Seigler, H.F.; Darrow, T.L.; Paterson, H.; Marais, R.; Marshall, C.J.; Wooster, R.; Stratton, M.R.; Futreal, P.A. Mutations of the BRAF gene in human cancer.
Nature, 2002,
417(6892), 949-954.
[
http://dx.doi.org/10.1038/nature00766] [PMID:
12068308]
[123]
Details available in treatment of colorectal cancer segment of cancer.gov database. 2011.
[156]
Vijayan, D.; Young, A.; Teng, M.W.L.; Smyth, M.J. Targeting immunosuppressive adenosine in cancer. Nat. Rev. Cancer, 2017, 17, 70.
[157]
Mariathasan, S.; Turley, S.J.; Nickles, D.; Castiglioni, A.; Yuen, K.; Wang, Y.; Kadel, E.E., III; Koeppen, H.; Astarita, J.L.; Cubas, R.; Jhunjhunwala, S.; Banchereau, R.; Yang, Y.; Guan, Y.; Chalouni, C.; Ziai, J.; Şenbabaoğlu, Y.; Santoro, S.; Sheinson, D.; Hung, J.; Giltnane, J.M.; Pierce, A.A.; Mesh, K.; Lianoglou, S.; Riegler, J.; Carano, R.A.D.; Eriksson, P.; Höglund, M.; Somarriba, L.; Halligan, D.L.; van der Heijden, M.S.; Loriot, Y.; Rosenberg, J.E.; Fong, L.; Mellman, I.; Chen, D.S.; Green, M.; Derleth, C.; Fine, G.D.; Hegde, P.S.; Bourgon, R.; Powles, T. TGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells.
Nature, 2018,
554(7693), 544-548.
[
http://dx.doi.org/10.1038/nature25501] [PMID:
29443960]
[173]
Akdis, M.; Aab, A.; Altunbulakli, C.; Azkur, K.; Costa, R.A.; Crameri, R.; Duan, S.; Eiwegger, T.; Eljaszewicz, A.; Ferstl, R.; Frei, R.; Garbani, M.; Globinska, A.; Hess, L.; Huitema, C.; Kubo, T.; Komlosi, Z.; Konieczna, P.; Kovacs, N.; Kucuksezer, U.C.; Meyer, N.; Morita, H.; Olzhausen, J.; O’Mahony, L.; Pezer, M.; Prati, M.; Rebane, A.; Rhyner, C.; Rinaldi, A.; Sokolowska, M.; Stanic, B.; Sugita, K.; Treis, A.; van de Veen, W.; Wanke, K.; Wawrzyniak, M.; Wawrzyniak, P.; Wirz, O.F.; Zakzuk, J.S.; Akdis, C.A. Interleukins (from IL-1 to IL-38), interferons, transforming growth factor β, and TNF-α: Receptors, functions, and roles in diseases.
J. Allergy Clin. Immunol., 2016,
138(4), 984-1010.
[
http://dx.doi.org/10.1016/j.jaci.2016.06.033] [PMID:
27577879]
[201]
Rejhová, A.; Opattová, A.; Čumová, A.; Slíva, D.; Vodička, P. Natural compounds and combination therapy in colorectal cancer treatment. Eur J Med Chem., 2017, 144, 582-594.